GLP-1 derivatives Mojsov synthesized were patented as peptides

a hormone generated by the gut that triggers the release of insulin. The amino acid sequence of GLP-1 was similar to a gastric inhibitory peptide, an incretin. To try to identify whether a specific fragment of GLP-q was an incretin, Mojsov created an incretin-antibody and developed ways to track its presence. Specifically, Mojsov identified that a stretch of 31 amino acids in the GLP-1 was an incretin.[2][3] Together with Daniel J. Drucker and Habener, Mojsov showed that small quantities of lab-synthesized GLP-1 could trigger insulin.

Category:
Chemistry

Completion Status:
yes

Patent Number:
N/A